<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189267</url>
  </required_header>
  <id_info>
    <org_study_id>1443-IMIQ</org_study_id>
    <nct_id>NCT00189267</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients</brief_title>
  <official_title>Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days Per Week for the Treatment of Actinic Keratoses in Immunosuppressed Organ Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare effectiveness and safety of multiple applications of
      imiquimod 5% cream and vehicle cream in graft recipients suffering from actinic keratosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome of the study is to compare imiquimod 5% cream and vehicle cream with respect to safety assessments in graft recipients.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome of the study is to compare imiquimod 5% cream and vehicle cream with respect to complete and partial clearance rates.</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Actinic Keratosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod 5 % Cream</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a total of 4-10 actinic keratosis (AK) lesions located on either face or scalp

          -  If female and of childbearing potential, have a negative urine pregnancy test at
             treatment initiation, and willing to use a medically acceptable method of
             contraception during the treatment period

          -  Renal, liver or heart transplant recipients

        Exclusion Criteria:

          -  Graft rejection with loss of the graft in the medical history

          -  Unstable status of organ transplant disease during the last 12 months

          -  Known to be pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaetsklinikum Charite</affiliation>
  </overall_official>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>November 19, 2010</last_update_submitted>
  <last_update_submitted_qc>November 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2010</last_update_posted>
  <keyword>Aldara</keyword>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Graft Recipients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

